AstraZeneca (LON:AZN) has been assigned a GBX 4,080 ($53.31) price target by stock analysts at Goldman Sachs Group in a report issued on Thursday. The brokerage presently has a “sell” rating on the biopharmaceutical company’s stock. Goldman Sachs Group’s price target would indicate a potential downside of 33.90% from the company’s previous close.
Several other analysts also recently weighed in on the company. UBS Group set a GBX 5,900 ($77.09) price objective on AstraZeneca and gave the company a “neutral” rating in a report on Thursday. Bryan, Garnier & Co downgraded AstraZeneca to a “neutral” rating in a report on Thursday. Liberum Capital restated a “hold” rating on shares of AstraZeneca in a report on Thursday. Shore Capital restated a “hold” rating on shares of AstraZeneca in a report on Tuesday. Finally, JPMorgan Chase & Co. restated a “buy” rating on shares of AstraZeneca in a report on Tuesday, October 30th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of GBX 5,831.89 ($76.20).
AZN stock opened at GBX 6,172 ($80.65) on Thursday. AstraZeneca has a 1-year low of GBX 4,260 ($55.66) and a 1-year high of GBX 5,520 ($72.13).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
See Also: Why do companies engage in swaps?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.